"Souhrn \u00DAvod: C\u00EDlem na\u0161\u00ED pr\u00E1ce bylo srovn\u00E1n\u00ED zdravotnick\u00FDch n\u00E1klad\u016F na terapii re\u017Eimy XELOX a FOLFOX-4 u nemocn\u00FDch s kolorekt\u00E1ln\u00EDm karcinomem. Posuzovali jsme n\u00E1klady vykazovan\u00E9 zdravotn\u00ED poji\u0161\u0165ovn\u011B nemocnic\u00ED, v n\u00ED\u017E onkologick\u00E1 l\u00E9\u010Dba prob\u00EDhala. Jedn\u00E1 se o pilotn\u00ED projekt s vyu\u017Eit\u00EDm nov\u00E9 datab\u00E1ze I-COP vyvinut\u00E9 Institutem biostatistiky a anal\u00FDz Masarykovy univerzity. Pacienti a metody: P\u0159edpokl\u00E1dan\u00E9 n\u00E1klady na oba re\u017Eimy jsme nejd\u0159\u00EDve odhadli na z\u00E1klad\u011B zdravotnick\u00FDch v\u00FDkon\u016F a maxim\u00E1ln\u00EDch \u00FAhrad l\u00E9k\u016F/materi\u00E1lu. Pomoc\u00ED datab\u00E1ze v\u00FDkon\u016F vykazovan\u00FDch zdravotn\u00EDm poji\u0161\u0165ovn\u00E1m jsme pot\u00E9 provedli p\u00E1rov\u00E9 srovn\u00E1n\u00ED 26 pacient\u016F l\u00E9\u010Den\u00FDch re\u017Eimem FOLFOX-4 nebo XELOX pro kolorekt\u00E1ln\u00ED karcinom. Hodnotili jsme obdob\u00ED prvn\u00EDch 3 m\u011Bs\u00EDc\u016F terapie (tj. 6 cykl\u016F FOLFOX-4 nebo 4 cykl\u016F XELOX). Statistick\u00E1 v\u00FDznamnost rozd\u00EDl\u016F byla hodnocena p\u00E1rov\u00FDm Wilcoxonov\u00FDm testem. V\u00FDsledky: Odhadnut\u00E9 celkov\u00E9 n\u00E1klady na t\u0159\u00EDm\u011Bs\u00ED\u010Dn\u00ED l\u00E9\u010Dbu byly pro re\u017Eim FOLFOX-4 133 651 K\u010D (z toho 92 719 K\u010D n\u00E1klady na l\u00E9ky) a pro re\u017Eim XELOX 115 999 K\u010D (z toho 110 715 K\u010D n\u00E1klady na l\u00E9ky). Skute\u010Dn\u011B vyk\u00E1zan\u00E9 n\u00E1klady l\u00E9\u010Dby FOLFOX-4 byly 160 158 K\u010D ve srovn\u00E1n\u00ED s 151 176 K\u010D pro re\u017Eim XELOX (p = 0,221). U re\u017Eimu XELOX byly signifikantn\u011B vy\u0161\u0161\u00ED n\u00E1klady na l\u00E9ky (131 705 K\u010D vs 114 531 K\u010D, p = 0,023) p\u0159i v\u00FDznamn\u011B ni\u017E\u0161\u00EDch ostatn\u00EDch n\u00E1kladech. Z\u00E1v\u011Br: Re\u017Eimy FOLFOX-4 a XELOX lze pova\u017Eovat za ekvivalentn\u00ED, co se t\u00FD\u010De n\u00E1klad\u016F vykazovan\u00FDch zdravotn\u00ED poji\u0161\u0165ovn\u011B nemocnic\u00ED, v n\u00ED\u017E onkologick\u00E1 terapie prob\u00EDh\u00E1." . . . "B\u00FCchler, Tom\u00E1\u0161" . "0862-495X" . "Porovn\u00E1n\u00ED n\u00E1klad\u016F u re\u017Eim\u016F XELOX a FOLFOX-4 v l\u00E9\u010Db\u011B kolorekt\u00E1ln\u00EDho karcinomu" . . . . . "Porovn\u00E1n\u00ED n\u00E1klad\u016F u re\u017Eim\u016F XELOX a FOLFOX-4 v l\u00E9\u010Db\u011B kolorekt\u00E1ln\u00EDho karcinomu" . "RIV/00064190:_____/12:#0000361!RIV13-MZ0-00064190" . . "Souhrn \u00DAvod: C\u00EDlem na\u0161\u00ED pr\u00E1ce bylo srovn\u00E1n\u00ED zdravotnick\u00FDch n\u00E1klad\u016F na terapii re\u017Eimy XELOX a FOLFOX-4 u nemocn\u00FDch s kolorekt\u00E1ln\u00EDm karcinomem. Posuzovali jsme n\u00E1klady vykazovan\u00E9 zdravotn\u00ED poji\u0161\u0165ovn\u011B nemocnic\u00ED, v n\u00ED\u017E onkologick\u00E1 l\u00E9\u010Dba prob\u00EDhala. Jedn\u00E1 se o pilotn\u00ED projekt s vyu\u017Eit\u00EDm nov\u00E9 datab\u00E1ze I-COP vyvinut\u00E9 Institutem biostatistiky a anal\u00FDz Masarykovy univerzity. Pacienti a metody: P\u0159edpokl\u00E1dan\u00E9 n\u00E1klady na oba re\u017Eimy jsme nejd\u0159\u00EDve odhadli na z\u00E1klad\u011B zdravotnick\u00FDch v\u00FDkon\u016F a maxim\u00E1ln\u00EDch \u00FAhrad l\u00E9k\u016F/materi\u00E1lu. Pomoc\u00ED datab\u00E1ze v\u00FDkon\u016F vykazovan\u00FDch zdravotn\u00EDm poji\u0161\u0165ovn\u00E1m jsme pot\u00E9 provedli p\u00E1rov\u00E9 srovn\u00E1n\u00ED 26 pacient\u016F l\u00E9\u010Den\u00FDch re\u017Eimem FOLFOX-4 nebo XELOX pro kolorekt\u00E1ln\u00ED karcinom. Hodnotili jsme obdob\u00ED prvn\u00EDch 3 m\u011Bs\u00EDc\u016F terapie (tj. 6 cykl\u016F FOLFOX-4 nebo 4 cykl\u016F XELOX). Statistick\u00E1 v\u00FDznamnost rozd\u00EDl\u016F byla hodnocena p\u00E1rov\u00FDm Wilcoxonov\u00FDm testem. V\u00FDsledky: Odhadnut\u00E9 celkov\u00E9 n\u00E1klady na t\u0159\u00EDm\u011Bs\u00ED\u010Dn\u00ED l\u00E9\u010Dbu byly pro re\u017Eim FOLFOX-4 133 651 K\u010D (z toho 92 719 K\u010D n\u00E1klady na l\u00E9ky) a pro re\u017Eim XELOX 115 999 K\u010D (z toho 110 715 K\u010D n\u00E1klady na l\u00E9ky). Skute\u010Dn\u011B vyk\u00E1zan\u00E9 n\u00E1klady l\u00E9\u010Dby FOLFOX-4 byly 160 158 K\u010D ve srovn\u00E1n\u00ED s 151 176 K\u010D pro re\u017Eim XELOX (p = 0,221). U re\u017Eimu XELOX byly signifikantn\u011B vy\u0161\u0161\u00ED n\u00E1klady na l\u00E9ky (131 705 K\u010D vs 114 531 K\u010D, p = 0,023) p\u0159i v\u00FDznamn\u011B ni\u017E\u0161\u00EDch ostatn\u00EDch n\u00E1kladech. Z\u00E1v\u011Br: Re\u017Eimy FOLFOX-4 a XELOX lze pova\u017Eovat za ekvivalentn\u00ED, co se t\u00FD\u010De n\u00E1klad\u016F vykazovan\u00FDch zdravotn\u00ED poji\u0161\u0165ovn\u011B nemocnic\u00ED, v n\u00ED\u017E onkologick\u00E1 terapie prob\u00EDh\u00E1."@cs . "Kupec, Martin" . . "Porovn\u00E1n\u00ED n\u00E1klad\u016F u re\u017Eim\u016F XELOX a FOLFOX-4 v l\u00E9\u010Db\u011B kolorekt\u00E1ln\u00EDho karcinomu"@cs . "CZ - \u010Cesk\u00E1 republika" . "Porovn\u00E1n\u00ED n\u00E1klad\u016F u re\u017Eim\u016F XELOX a FOLFOX-4 v l\u00E9\u010Db\u011B kolorekt\u00E1ln\u00EDho karcinomu"@cs . "159764" . . "4"^^ . . . "Comparing costs of XELOX and FOLFOX-4 in the treatment of colorectal cancer"@en . "5"^^ . "O, S, V" . . "Nohejlov\u00E1 Medkov\u00E1, Anna" . . . "RIV/00064190:_____/12:#0000361" . "The aim of our study was to compare the cost of medical treatment XELOX and FOLFOX-4 in patients with colorectal cancer. We assessed the cost of health insurance hospital reported in which cancer treatment is ongoing. This is a pilot project using a new database developed by I-COP Institute of Biostatistics and Analyses, Masaryk University. Patients and methods: The expected costs of both schemes, we first estimated on the basis of medical services and maximum payments for drugs / material. Using a database of performance reported by health insurers We then performed pairwise comparison of 26 patients treated with FOLFOX-4 or XELOX for colorectal cancer. We evaluated the first three months of therapy (ie, 6 cycles of FOLFOX-4 or XELOX 4 cycles). The statistical significance of differences was evaluated by paired Wilcoxon test. Results: The estimated total cost of the three-month treatment regime for FOLFOX-CZK 4,133,651 (of which 92 719 CZK cost of medicines) and XELOX CZK 115,999 (of which 110,715 CZK cost of drugs). Indeed the reported cost of treatment FOLFOX-4 160 158 were compared to CZK 151 176 CZK for XELOX (p = 0.221). The XELOX were significantly higher drug costs (131,705 vs. 114,531 CZK CZK, p = 0.023) at significantly lower other costs. Conclusion: FOLFOX-4 and XELOX can be considered equivalent in terms of cost reporting health insurance hospital in which cancer therapy is conducted."@en . "7"^^ . "costs and cost analysis; chemotherapy; colorectal carcinoma"@en . "Comparing costs of XELOX and FOLFOX-4 in the treatment of colorectal cancer"@en . . "[2864E2FE4E34]" . . "Klinick\u00E1 onkologie" . . . "Abrh\u00E1mov\u00E1, Jitka" . . "6" . . "25" .